Abstracts tagged "Psoriatic arthritis"

Abstract Number: 1757 • ACR Convergence 2025
Skin-to-Joint Immune Cell Migration and Synovial Reprogramming in Psoriatic Arthritis Onset
Maria Gabriella Raimondo¹, Hashem Mohammadian², Mario Angeli², Vladyslav Fedorchenko², Kaiyue Huang³, Yi-Nan Li⁴, Raphael Micheroli⁵, Jörg Distler⁶, Ursula Fearon⁷, Juergen Rech², Francesco Ciccia⁸, Juan Cañete⁹, Adam Croft¹⁰, Mariola Kurowska-Stolarska¹¹, Stefano Alivernini¹², Maria Antonietta D'Agostino¹³, Georg Schett², Simon Rauber¹⁴ and Andreas Ramming¹⁵, ¹Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ²Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ³Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, ⁴University Hospital of Düsseldorf, Düsseldorf, Germany, ⁵University Hospital Zurich, Zurich, Switzerland, ⁶University Hospital Duesseldorf and HHU, Duesseldorf, Germany, ⁷Trinity College Dublin, Dublin, Dublin, Ireland, ⁸Rheumatology Section, University of Campania L. Vanvitelli, Naples, Italy, Naples, Italy, ⁹Rheumatology Department, Hospital Clínic and IDIBAPS, Barcelona, Spain, Barcelona, Spain, ¹⁰University of Birmingham, Hagley, Stourbridge, United Kingdom, ¹¹University of Glasgow, Glasgow, ¹²Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ¹³Division of Rheumatology and Clinical Immunology - Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ¹⁴Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Bayern, Germany, ¹⁵Department of Internal Medicine ³, Rheumatology & Immunology, Friedrich-Alexander-University (FAU) & Universitätsklinikum Erlangen, Erlangen, Germany
Background/Purpose: Psoriatic arthritis (PsA) develops in about 30% of individuals with psoriasis (PsO), highlighting a critical connection between skin and joint inflammation. However, the mechanisms…
Abstract Number: 1455 • ACR Convergence 2025
Sonelokimab in Patients With Active Psoriatic Arthritis Who Are Naive to Biologic DMARDs: Phase 2 ARGO Analysis and Phase 3 IZAR-1 Study Design
Philip J. Mease¹, Laure Gossec², Atul Deodhar³, Xenofon Baraliakos⁴, Frank Behrens⁵, Joseph F Merola⁶, Lihi Eder⁷, Ana-Maria Orbai⁸, Andreas Ramming⁹, Iain McInnes¹⁰, Alexis Ogdie¹¹, Dennis McGonagle¹², Christopher Ritchlin¹³, Nuala Brennan¹⁴, Ben Porter-Brown¹⁴, Eva Cullen¹⁴, Matthew R. Thomas¹⁴, Marius Albulescu¹⁴, Alex Godwood¹⁴, Kristian Reich¹⁵ and Laura Coates¹⁶, ¹Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ²Sorbonne Universite and Pitie-Salpetriere Hospital, Paris, France, ³Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ⁴Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁵Rheumatology, Immunology - Inflammation Medicine, University Hospital Goethe-University & Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt am Main, Germany, ⁶Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX, ⁷University of Toronto, Toronto, ON, Canada, ⁸Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁹Department of Internal Medicine ³, Rheumatology & Immunology, Friedrich-Alexander-University (FAU) & Universitätsklinikum Erlangen, Erlangen, Germany, ¹⁰University of Glasgow, Glasgow, United Kingdom, ¹¹University of Pennsylvania, Philadelphia, PA, ¹²Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), University of Leeds, Leeds, United Kingdom, ¹³University of Rochester Medical Center, Canandaigua, NY, ¹⁴MoonLake Immunotherapeutics AG, Zug, Switzerland, ¹⁵MoonLake Immunotherapeutics AG and Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, Zug, Switzerland, ¹⁶Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom
Background/Purpose: Sonelokimab (SLK), a novel Nanobody that binds to both IL-17A and IL-17F with similarly high affinity, is designed to target difficult-to-reach sites of inflammation…
Abstract Number: 1415 • ACR Convergence 2025
The Association of Handedness with Radiographic Damage in Patients with Psoriatic Arthritis
Fadi Kharouf¹, Shahad Al-Matar², Virginia Carrizo Abarza³, Pankti Mehta⁴, Shangyi Gao⁵, Daniel Pereira⁶, Richard Cook⁷, Vinod Chandran⁸, Denis Poddubnyy⁹ and Dafna D. Gladman¹⁰, ¹University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ²University of alberta, Edmonton, AB, Canada, ³Toronto Western Hospital - University of Toronto, Toronto, ON, Canada, ⁴University of Toronto, Gladman Krembil Psoriatic Arthritis Research Program, Toronto, ON, Canada, ⁵Gladman-Krembil Psoriatic Arthritis Research Program, Centre for Prognosis Studies in the Rheumatic Diseases, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, Ontario, Canada, Toronto, ON, Canada, ⁶University Health Network, Toronto, ON, Canada, ⁷University of Waterloo, Waterloo, Canada, ⁸University of Toronto, Toronto, ON, Canada, ⁹Division of Rheumatology, Department of Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada, and Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany; Department of Epidemiology, German Rheumatism Research Centre, Berlin, Germany, ¹⁰Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada
Background/Purpose: Mechanical stress is known to trigger and exacerbate psoriatic arthritis (PsA). Based on the hypothesis that biomechanical stress is greater in the dominant extremity,…
Abstract Number: 0996 • ACR Convergence 2025
Breaking Inflammatory Pathways: ELN28, a Novel Dual TNFα/JAK Inhibitor Drug Conjugate for Chronic Inflammation
Obinna Ubah, Euan Murray, Stella Priyanka, Julia Martinez Fraile, Andrew Porter, Robert Boyd and Caroline Barelle, Elasmogen Limited, Aberdeen, United Kingdom
Background/Purpose: Despite advances in therapies for chronic autoimmune diseases such as rheumatoid arthritis (RA), significant unmet needs persist, including therapeutic ceiling effects, adverse events, and…
Abstract Number: 0563 • ACR Convergence 2025
Efficacy and Safety of Guselkumab in Patients with Active Psoriatic Arthritis and Inadequate Response and/or Intolerance to One Prior Tumor Necrosis Factor Inhibitor
Alexis Ogdie¹, Joseph F Merola², Philip J. Mease³, Christopher Ritchlin⁴, Jose U. Scher⁵, Kimberly Parnell Lafferty⁶, Daphne Chan⁷, Soumya Chakravarty⁸, Wayne Langholff⁹, Yanli Wang⁹, Olivia Choi, MD, PhD, FAAD⁷, Yevgeniy Krol¹⁰ and Alice Gottlieb¹¹, ¹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Wilmington, DE, ²Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX, ³Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ⁴University of Rochester Medical Center, Canandaigua, NY, ⁵New York University School of Medicine, New York, NY, ⁶Johnson & Johnson, Dermatology, Horsham, PA, ⁷Johnson & Johnson, Horsham, PA, USA, Horsham, PA, ⁸Johnson & Johnson, Horsham, PA, USA; Drexel University College of Medicine, Philadelphia, PA, USA, Villanova, PA, ⁹Johnson & Johnson, Biostatistics, Spring House, PA, ¹⁰Johnson & Johnson, Horsham, PA, ¹¹Department of Dermatology, UT Southwestern Medical Center, Dallas, TX
Background/Purpose: Guselkumab (GUS), a fully human IL-23p19-subunit inhibitor, has demonstrated efficacy in significantly improving psoriatic arthritis (PsA) signs and symptoms with two dosing regimens: 100…
Abstract Number: 0536 • ACR Convergence 2025
Can achieving sustained low disease activity through treat-to-target management arrest enthesiophyte progression in psoriatic arthritis? A two-year prospective study using high resolution peripheral quantitative computed tomography
Isaac Cheng¹, Ho So¹, Yingzhao jin¹, Vivian Hung², Ling Qin², James Griffith³ and Lai Shan Tam¹, ¹Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ²Bone Quality and Health Centre, Department of Orthopaedics and Traumatology, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ³Department of Imaging and Interventional Radiology, The Chinese University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose: Enthesitis is a hallmark feature of psoriatic arthritis (PsA). Chronic inflammation in the entheses can lead to the formation of enthesiophytes (bony spurs), and…
Abstract Number: 0275 • ACR Convergence 2025
A snapshot of subcutaneous infliximab use in inflammatory rheumatic diseases: a multicenter Italian study
Stefano Gentileschi¹, Carla Gaggiano¹, Francesco Placido¹, Riccardo Terribili¹, Laura Cometi², Giuseppe Lopalco³, Greta Dipetrangelo³, Giacomo Cozzi⁴, Roberto Padoan⁵, Riccardo Bixio⁶, Simone Parisi⁷, Maria Chiara Ditto⁸, Gemma Lepri⁹, Caludia Fabiani¹⁰, Luca Cantarini¹, Florenzo Iannone¹¹, Roberta Ramonda¹², Bruno Frediani¹ and Serena Guiducci², ¹Rheumatology Unit, Department of Medicine, Surgery and Neurosciences, University Hospital of Siena, Siena, Italy, Siena, Italy, ²Division of Rheumatology, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, Florence, Italy, ³Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University o f Bari, Bari, Italy, Bari, Italy, ⁴Rheumatology Unit, Department of Medicine, University of Padua, Padua, Italy, Padua, Italy, ⁵Rheumatology Unit, Department of Medicine DIMED, University of Padua, Padua, Italy, ⁶Rheumatology Unit, IRCCS Sacro Cuore Don Calabria Hospital, Negrar, Verona, Italy, Verona, Italy, ⁷Ospedaliera Universitaria Città della Salute e della Scienza di Torino, Turin, Italy, ⁸SC Reumatologia, AOU Città della Salute e della Scienza, Torino, Italy, Turin, Italy, ⁹Department of Experimental and Clinical Medicine, University of Florence, Division of Rheumatology Scleroderma Unit, AOU Careggi Hospital, Florence, Italy., Florence, Italy, ¹⁰Ophthalmology Unit, Department of Medical Sciences, Surgery and Neuroscience, University of Siena, Siena University Hospital [European Reference Network (ERN) for Rare Immunodeficiency, Autoinflammatory and Autoimmune Diseases (RITA) Center], Siena, Italy, Siena, Italy, ¹¹Rheumatology DiMePReJ, University of Bari, School of Medicine, Bari, Italy, Bari, Italy, ¹²Rheumatology Unit-DIMED-University of Padova ITALY, Padova, Padua, Italy
Background/Purpose: A new subcutaneous formulation of infliximab (CT-P13) has recently become available for the treatment of inflammatory rheumatic diseases (IRDs), psoriasis and inflammatory bowel diseases.…
Abstract Number: 0074 • ACR Convergence 2024
Tofacitinib Therapy Ameliorates Inflammation in a Mouse Model of Psoriasis and Arthritis by Inducing Type 2 Immunity
Maria de la Luz Garcia-Hernandez¹, Javier Rangel-Moreno¹, Ananta Paine², Angel Rangel-Garcia¹, Marissa Krantz³, Delaney Martino¹, Marc Nuzzo¹ and Christopher Ritchlin⁴, ¹University of Rochester, Rochester, NY, ²ORNA Tx, Southborough, MA, ³University of Rochester, Rochester, NY, ⁴Department of Medicine, Allergy, Immunology, and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY
Background/Purpose: Psoriatic arthritis (PsA), a chronic progressive inflammatory arthritis, affects peripheral joints and causes patient disability. PsA patients also have skin plaques initiated by activation…
Abstract Number: 0384 • ACR Convergence 2024
Pharmacokinetics of Ustekinumab in Patients with Juvenile Psoriatic Arthritis in a Real‑World Opportunistic Study
Corey J. Bishop¹, Edwin Lam², Sophia G. Liva³, Jocelyn H. Leu², Amy S. Paller⁴, Lucia Z. Diaz⁵, Laura Wine Lee⁶, Cory Rubin⁷, Ruy Carrasco⁸, Lisa Imundo⁹, Azadeh Majlessi¹⁰, Katherine Berezny¹, Kathleen G. Lomax¹, Valerie Smith¹, Renping Zhang¹ and hermine brunner¹¹, ¹Janssen Research & Development, Spring House, PA, ²Janssen Research & Development, LLC, a Johnson & Johnson company, Spring House, PA, PA, ³Janssen Research & Development, LLC, a Johnson & Johnson Company, Spring House, PA, ⁴Northwestern University, Feinberg School of Medicine, Chicago, IL, ⁵Dell Children’s Medical Center; Dell Medical School at the University of Texas at Austin, Austin, TX, ⁶Medical University of South Carolina, Charleston, SC, ⁷Michigan Dermatology Institute, Waterford, MI, ⁸Pediatric Rheumatology Consultants of Austin, Austin, TX, ⁹Columbia University Medical Center, New York, NY, ¹⁰Newport Huntington Medical Group, Huntington Beach, CA, ¹¹Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH
Background/Purpose: Ustekinumab (UST), an interleukin‑12/23p40 antagonist, is currently approved for juvenile psoriatic arthritis (jPsA) solely in the United States (US). Although a phase 3 study…
Abstract Number: 0593 • ACR Convergence 2024
Value of the Routine Assessment of Patient Index Data 3 in Assessing Disease Severity and Treatment Effect in Patients with Early Oligoarticular Psoriatic Arthritis Treated with Apremilast
Alvin F. Wells¹, Arthur Kavanaugh², William Tillett³, Philip S. Helliwell⁴, Marijn Vis⁵, Yuri Klyachkin⁶, Cynthia Deignan⁷, Lichen Teng⁷, Rebecca Wang⁷ and Alexis Ogdie⁸, ¹Rheumatology and Immunotherapy Center, Franklin, WI, ²University of California San Diego, La Jolla, CA, ³Royal National Hospital of Rheumatic Diseases; Department of Life Sciences, Centre for Therapeutic Innovation, University of Bath, Bath, United Kingdom, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK, Leeds, United Kingdom, ⁵Erasmus MC, Rotterdam, Netherlands, ⁶Amgen, Lexington, KY, ⁷Amgen Inc., Thousand Oaks, CA, ⁸Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: The Routine Assessment of Patient Index Data 3 (RAPID3) score is a composite of 3 patient-reported outcomes (PROs): Health Assessment Questionnaire (HAQ), pain visual…
Abstract Number: 1019 • ACR Convergence 2024
The Impact of Race and Ethnicity and Historical Redlining on Psoriatic Disease Burden
Brittany Banbury¹, Sharon Dowell², Christopher Jenkins³, Emily Holladay⁴, Fenglong Xie⁵, Jingyi Zhang⁵, Grace Wright⁶, Jeffrey Curtis⁷ and Gail Kerr⁸, ¹Mount Sinai Beth Israel, Brooklyn, NY, ²NEA Baptist Memorial Hospital, JONESBORO, AR, ³Medstar Georgetown University Hospital, Washington, DC, ⁴University of Alabama at Birmingham, Edmond, OK, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Grace C Wright MD PC, New York, NY, ⁷University of Alabama at Birmingham, Hoover, AL, ⁸Washington DC VAMC/Georgetown and Howard Universities, Washington, DC
Background/Purpose: Previous literature has suggested racial and ethnic variations in the clinical expression of psoriatic disease, with Non-White patients having more extensive skin disease, higher…
Abstract Number: 1436 • ACR Convergence 2024
The Association of Cigarette Smoking with Radiographic Progression in Psoriatic Arthritis
Fadi Kharouf¹, Hernan Maldonado Ficco², Shangyi Gao³, barry J Sheanne⁴, Daniel Pereira⁵, Richard Cook⁶, Vinod Chandran⁷ and Dafna Gladman⁸, ¹University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ²Hospital San Antonio de Padua, Cordoba, Argentina, ³Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ⁴St James' Hospital, Dublin, Ireland, ⁵University Health Network, Toronto, ON, Canada, ⁶University of Waterloo, Waterloo, Canada, ⁷University of Toronto, Toronto, ON, Canada, ⁸University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: The association between smoking and radiographic damage has been established in axial spondyloarthritis and rheumatoid arthritis, but not in psoriatic arthritis (PsA). We designed…
Abstract Number: 1472 • ACR Convergence 2024
Achievement of Low Disease Activity/Remission in Guselkumab-Treated Patients with Moderately-Highly Active Psoriatic Arthritis Regardless of Baseline Characteristics: Pooled Post-Hoc Analysis of Two Phase 3/Randomized Studies
Philip Mease¹, Alice Gottlieb², Iain McInnes³, Natalie J. Shiff⁴, Anthony Todd⁵, Emmanouil Rampakakis⁶, Francois Nantel⁷, Jenna Parrett⁵, Frederic Lavie⁸ and Proton Rahman⁹, ¹Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, ²Icahn School of Medicine at Mount Sinai, Department of Dermatology, Seattle, WA, ³University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, United Kingdom, ⁴Janssen Scientific Affairs, LLC / University of Saskatchewan, Adjunct, Community Health and Epidemiology, Horsham, PA, ⁵Janssen Scientific Affairs, LLC, Horsham, PA, ⁶McGill University, Department of Pediatrics / Scientific Affairs, JSS Medical Research Inc., Montreal, QC, Canada, ⁷Nantel Medsci Consult, Montreal, QC, Canada, ⁸Janssen Cilag Global Medical Affairs, Immunology Global Medical Affairs, Issy les Moulineaux, France, ⁹Memorial University of Newfoundland, Faculty of Medicine, Division of Rheumatology, St. John's, Canada
Background/Purpose: Guselkumab (GUS), a fully human IL-23p19-subunit inhibitor, has demonstrated multidomain efficacy (swollen/tender joints, psoriasis, enthesitis and dactylitis) in patients (pts) with active PsA in…
Abstract Number: 1935 • ACR Convergence 2024
Timely Referral of Patients with Inflammatory Rheumatic Diseases to Rheumatology: Validation of a Referral Algorithm with Frontline Physicians
Nelly Ziade¹, Karen Mechleb², Nizar Ani³, avin maroof⁴, ASAL ADNAN RIDHA⁵, Manal El Rakawi⁶, Chafika Haouichat⁶, Bassel Elzorkany⁷, Sherif Gamal⁸, Mariama Erraoui⁹, Manal Al-Mashaleh¹⁰, Fatima Alnaimat¹¹, Basel masri¹², fatemah Baron¹³, Lina El Kibbi¹⁴, Krystel Aouad¹⁵ and Ihsane Hmamouchi¹⁶, and ARCH - ArLAR, ¹Saint-Joseph University, Beirut, Lebanon, ²Saint Joseph University Beirut, Beirut, Lebanon, ³Baghdad College of Medicine, Baghdad, Iraq, ⁴University of Kurdistan Hawler, Erbil, Iraq, ⁵Baghdad Teaching Hospital, baghdad, Iraq, ⁶Djillali Bounaama University Hospital, Algiers, Algeria, ⁷Private (BZRC), Cairo, Egypt, ⁸Cairo University, Cairo, Egypt, ⁹Souss Massa Univeristy, Rabat, Morocco, ¹⁰Royal Medical Services, Amman, Jordan, ¹¹University of Jordan, Amman, Jordan, ¹²Jordan Hospital and Medical Center, Amman, Jordan, ¹³Al-Jahra Hospital, Ministry of Health, Kuwait, Kuwait, ¹⁴Specialized Medical Center, Riyadh, Saudi Arabia, ¹⁵Saint George Hospital University Medical Center, Beirut, Lebanon, ¹⁶Rheumatology Unit, Lalla Aicha Temara Hospital, Temara, Rabat, Morocco
Background/Purpose: Early referral of patients with chronic inflammatory rheumatic diseases (CIRDs) to rheumatology is essential to reduce diagnostic delays and improve long-term prognosis. Referral strategies…
Abstract Number: 2319 • ACR Convergence 2024
Investigating the Association of Serum Metabolites with Psoriatic Arthritis Musculoskeletal Disease Patterns
Sheng Han Li¹, Nikita Looby², Max Kotiyar³, Lihi Eder⁴, Igor Jurisica⁵, Vathany Kulasingam⁶ and vinod Chandran⁷, ¹Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada, ²Psoriatic Arthritis Program Schroeder Arthritis Institute, Toronto, Canada, ³Data Science Discovery Centre for Chronic Dsiease, Krembil Research Institute, Toronto, Canada, ⁴University of Toronto, Women’s College Hospital and Department of Medicine, Toronto, ON, Canada, ⁵Data Science Discovery Centre, Krembil Research Institute, Toronto, Canada, ⁶Laboratory Medicine Program, Unviersity Health Network, Toronto, Canada, ⁷Toronto Western Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: Accurate assessment of disease patterns may be important for appropriate management of psoriatic arthritis (PsA). Ultrasonography (USG) is a highly accurate, sensitive, and non-invasive…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].